Lundbeck's Vyepti Sales Pick Up Against Pandemic Headwinds
Narrows Financial Guidance For 2020
Executive Summary
Lundbeck also makes progress in the third quarter with its early clinical-stage neuroscience candidates and indication extension studies for its psychiatry products, while confirming and narrowing revenues and earnings forecasts for the year.
You may also be interested in...
Migraine & Hepatitis B Prevention Products Among New EU Filings
The latest list of marketing authorization applications under review by the European Medicines Agency includes filings for eight new products.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.